6.8 million doses of vaccination in the United States… “A rare but cerebral sinus thrombosis”
WHO “waits for US and European J&J vaccine review”
J&J has delayed the launch of its Corona 19 vaccine in Europe. /Photo = Reuters
On the 13th (local time), the U.S. health authorities recommended that the use of a novel coronavirus infection (Corona 19) vaccine developed by Janssen, a subsidiary of Johnson & Johnson (J&J), be discontinued. Six of the vaccinated Americans developed blood clots.
The Associated Press, CNN, Reuters and other foreign media said, “The US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) issued a statement of discontinuation of this vaccine.” He said he advised us to stop.”
The joint statement is reviewing six cases of thrombosis in a’rare and severe’ form in people who received the Janssen-developed vaccine. The thrombosis that appeared this time is cerebral sinus thrombosis (CVST), which is known to be accompanied by platelet reduction. All vaccinations with thrombosis were female, aged 18-48. Symptoms occurred 6 to 13 days after vaccination. One Nebraska woman died of complications, and another patient was known to be in critical condition.
According to CDC data, in the United States, 6.8 million doses of the J&J vaccine were vaccinated up to the day before. An additional 9 million vaccines were delivered to each state. J&J had promised to supply 100 million batches by the end of May.
CDC will review cases of thrombosis after J&J vaccination at the Vaccination Advisory Committee (ACIP) on the 14th and evaluate the’potential significance’. Afterwards, FDA will analyze the CDC evaluation and conduct individual case investigations.
J&J issued a statement shortly after the recommendation to discontinue use, saying, “We are reviewing these cases with European health authorities.”
J&J vaccine is a’viral vector vaccine’ that uses adenovirus as a platform along with AstraZeneca (AZ) vaccine. Unlike the AZ vaccine, it is possible to expect a preventive effect with only one vaccination, and the advantage of being stored at a normal refrigerator temperature has been highlighted. The World Health Organization (WHO), the United States, the EU, and Canada have approved the emergency use of the J&J vaccine. Korea also issued a J&J vaccine product license on the 7th.
Kim Hana, reporter Hankyung.com [email protected]
Ⓒ Hankyung.com prohibits unauthorized reproduction and redistribution